211 related articles for article (PubMed ID: 32856975)
1. High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study.
Behrens F; Rech J; Thaçi D; Zinke S; Rothnie KJ; Oefner Daamen C; Leipe J
Mod Rheumatol; 2022 Jan; 32(1):87-95. PubMed ID: 32856975
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015.
Lee MP; Lii J; Jin Y; Desai RJ; Solomon DH; Merola JF; Kim SC
Arthritis Care Res (Hoboken); 2018 May; 70(5):791-796. PubMed ID: 28804988
[TBL] [Abstract][Full Text] [Related]
3. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Walsh JA; Pei S; Penmetsa GK; Sauer BC; Patil V; Walker JH; Clewell J; Douglas KM; Clegg DO; Cannon GW; Halwani A
J Manag Care Spec Pharm; 2019 Nov; 25(11):1218-1228. PubMed ID: 31663467
[TBL] [Abstract][Full Text] [Related]
5. Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian study.
Tymms K; Kelly A; Bird P; Griffiths H; de Jager J; Littlejohn G; Louw S; Roberts L; Youssef P; Zochling J; Nichols D
Int J Rheum Dis; 2018 Feb; 21(2):510-516. PubMed ID: 28730757
[TBL] [Abstract][Full Text] [Related]
6. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients.
Simon D; Kleyer A; Bayat S; Tascilar K; Kampylafka E; Meinderink T; Schuster L; Petrov R; Liphardt AM; Rech J; Schett G; Hueber AJ
Arthritis Res Ther; 2019 Jul; 21(1):162. PubMed ID: 31269973
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
Lubrano E; De Socio A; Perrotta FM
J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
[TBL] [Abstract][Full Text] [Related]
8. Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment.
Sparks JA; Lesperance T; Accortt NA; Solomon DH
Arthritis Care Res (Hoboken); 2019 Apr; 71(4):512-520. PubMed ID: 29799667
[TBL] [Abstract][Full Text] [Related]
9. Switching biologics in the treatment of psoriatic arthritis.
Merola JF; Lockshin B; Mody EA
Semin Arthritis Rheum; 2017 Aug; 47(1):29-37. PubMed ID: 28363434
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.
Zhang HF; Gauthier G; Hiscock R; Curtis JR
Arthritis Res Ther; 2014 Aug; 16(4):420. PubMed ID: 25146329
[TBL] [Abstract][Full Text] [Related]
11. LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan.
Okada M; Kurimoto S; Ganz F; Boehncke WH
PLoS One; 2021; 16(1):e0245954. PubMed ID: 33503031
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
[TBL] [Abstract][Full Text] [Related]
13. Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.
Tillett W; Allen A; Tucker L; Chandler D; Ciurtin C; Davis C; Dick A; Foulkes A; Gullick N; Helliwell P; Jadon D; Jones G; Kyle S; Madhok V; McHugh N; Parkinson A; Raine T; Siebert S; Smith C; Coates LC
Rheumatology (Oxford); 2021 Apr; 60(4):1588-1592. PubMed ID: 33097948
[TBL] [Abstract][Full Text] [Related]
14. Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance.
Walsh JA; Pei S; Burningham Z; Penmetsa G; Cannon GW; Clegg DO; Sauer BC
J Rheumatol; 2018 Mar; 45(3):430-436. PubMed ID: 29142040
[TBL] [Abstract][Full Text] [Related]
15. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
16. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Gossec L; Smolen JS; Ramiro S; de Wit M; Cutolo M; Dougados M; Emery P; Landewé R; Oliver S; Aletaha D; Betteridge N; Braun J; Burmester G; Cañete JD; Damjanov N; FitzGerald O; Haglund E; Helliwell P; Kvien TK; Lories R; Luger T; Maccarone M; Marzo-Ortega H; McGonagle D; McInnes IB; Olivieri I; Pavelka K; Schett G; Sieper J; van den Bosch F; Veale DJ; Wollenhaupt J; Zink A; van der Heijde D
Ann Rheum Dis; 2016 Mar; 75(3):499-510. PubMed ID: 26644232
[TBL] [Abstract][Full Text] [Related]
17. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era.
Haugeberg G; Michelsen B; Kavanaugh A
RMD Open; 2020 May; 6(1):. PubMed ID: 32409518
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.
Lorenzin M; Ortolan A; Cozzi G; Calligaro A; Favaro M; Del Ross T; Doria A; Ramonda R
Clin Rheumatol; 2021 Nov; 40(11):4569-4580. PubMed ID: 34136971
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing.
Pontifex EK; Dissanayake K; Bursill D; Gill T
Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819
[TBL] [Abstract][Full Text] [Related]
20. Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis in the United States: A Multicenter Observational Study.
Mease PJ; Liu C; Siegel E; Richmond H; Wu M; Chen L; Douglas K; Lockshin B
Am J Clin Dermatol; 2019 Dec; 20(6):873-880. PubMed ID: 31612380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]